People · Operator
Named in public records as an officer, director or promoter · active 2014–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc. | — | Biotechnology | Series A | $11.4M | $274.7M | 2014 |
| Arch Biopartners Inc. | — | Biotechnology | Pre-Seed | $561K | $14.6M | 2015 |
Adrian Haigh at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adrian Haigh on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rostislav Raykov | 1 | 3 |
| Chris A. Rallis | 1 | 3 |
| Andrew Bishop | 1 | 2 |
| Chris Rallis | 1 | 2 |
| Claude Allary | 1 | 2 |
| Daniel Muruve | 1 | 1 |
| Richard Rossman | 1 | 1 |
| Rotislav Raykov | 1 | 1 |
| Conor Gunne | 1 | 1 |
| Krysia Lynes | 1 | 1 |
| Steven Skolsky | 1 | 1 |
| Khalid Islam | 1 | 1 |
| Richard Muruve | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.